Paris (France), 31 January 2008 - Ipsen (Euronext: FR0010259150; IPN) announced that the Food and Drug Administration (FDA) has accepted the filing of its BLA for Dysport® in the United States to treat patients with cervical dystonia. This acceptance signifies the start of the review process of the dossier... Ipsen's Press Release -
Friday, February 1, 2008
Ipsen, a Biologics License Application (BLA) for Dysport in cervical dystonia
Paris (France), 31 January 2008 - Ipsen (Euronext: FR0010259150; IPN) announced that the Food and Drug Administration (FDA) has accepted the filing of its BLA for Dysport® in the United States to treat patients with cervical dystonia. This acceptance signifies the start of the review process of the dossier... Ipsen's Press Release -
